Absci (NASDAQ:ABSI) Stock Rating Reaffirmed as Buy by BTIG Research

Absci (NASDAQ:ABSI)‘s stock had its “buy” rating reissued by investment analysts at BTIG Research in a note issued to investors on Thursday, Benzinga reports. They currently have a $16.00 target price on the stock. BTIG Research‘s price objective would suggest a potential upside of 75.05% from the stock’s current price.

Several other equities research analysts also recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Absci in a research note on Thursday, October 15th. Jefferies Financial Group assumed coverage on shares of Absci in a report on Thursday, October 29th. They set a “buy” rating and a $14.00 target price on the stock. JPMorgan Chase & Co. raised their price target on shares of Absci from $14.00 to $15.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. Wall Street Zen upgraded shares of Absci from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, KeyCorp upped their price objective on Absci from $16.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, October 16th. Eleven investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $15.00.

Absci Trading Down 9.7%

ABSI opened at $9.14 on Thursday. The stock’s 50-day moving average price is $9.66 and its 200 day moving average price is $6.78. Absci has a 12-month low of $2.24 and a 12-month high of $12.54. The firm has a market cap of $1.57 billion, a price-to-earnings ratio of -11.43 and a beta of 2.22.

Absci (NASDAQ:ABSI) last released its earnings results on Thursday, November 12th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The company had revenue of $0.30 million during the quarter, compared to the consensus estimate of $0.66 million. Absci had a negative return on equity of 61.71% and a negative net margin of 7,756.38%. On average, research analysts forecast that Absci will post -0.76 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in ABSI. Voya Investment Management LLC grew its stake in shares of Absci by 630.5% during the third quarter. Voya Investment Management LLC now owns 194,377 shares of the company’s stock worth $2,093,000 after purchasing an additional 167,770 shares in the last quarter. Vista Capital Partners Inc. acquired a new stake in Absci in the third quarter valued at $151,000. Russell Investments Group Ltd. raised its stake in Absci by 68.8% in the third quarter. Russell Investments Group Ltd. now owns 77,692 shares of the company’s stock valued at $837,000 after buying an additional 31,672 shares in the last quarter. Pier 88 Investment Partners LLC lifted its holdings in Absci by 59.8% during the 3rd quarter. Pier 88 Investment Partners LLC now owns 67,900 shares of the company’s stock worth $731,000 after buying an additional 25,400 shares during the last quarter. Finally, Pictet Asset Management Holding SA purchased a new stake in Absci during the 3rd quarter worth about $318,000. Hedge funds and other institutional investors own 52.05% of the company’s stock.

Recent Absci Headlines

Here are a few of the latest headlines about ABSI:

• Positive Sentiment: The company had $173.7 million in cash, cash equivalents and marketable securities at quarter-end, which it expects to fund operations into the second half of 2028. It also plans to start a Phase 2 ABS-201 trial for endometriosis in mid-2027. Article: Absci Reports Third-Quarter Results
• Neutral Sentiment: Absci appointed Gerry Muhle, a former executive at Galderma, Allergan and GSK, as chief commercial officer. The hire adds commercialization experience, though its impact will depend on progress in the pipeline. Article: Absci Appoints Gerry Muhle as Chief Commercial Officer
• Negative Sentiment: Quarterly revenue was $0.3 million, below the cited $0.66 million consensus estimate, while net loss widened to $33.3 million from $28.7 million a year earlier. The reported $0.19 loss per share met one consensus estimate, although another source said it missed its estimate—adding to the mixed earnings read-through. Article: Absci Reports Q3 Loss, Misses Revenue Estimates

About Absci

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.